Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Hematologic Diseases 1Glioma 1Blood Protein Disorders 1

Interventions

Rituximab 208Cyclophosphamide 167Etoposide 83Prednisone 79Vincristine 77Doxorubicin 76Peripheral Blood Stem Cell Transplantation 61Filgrastim 55Cytarabine 47fludarabine phosphate 46Radiotherapy 43Lenalidomide 41Mycophenolic Acid 40Tacrolimus 36Methotrexate 35Melphalan 35Busulfan 35Gemcitabine 32Carmustine 32Cyclosporine 31Whole-Body Irradiation 29Ifosfamide 28Antilymphocyte Serum 26zanubrutinib 25polatuzumab vedotin 25Dexamethasone 23Methylprednisolone 22ibritumomab tiuxetan 20Carboplatin 20Oxaliplatin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Large B-Cell, Diffuse × CLR1404 × Clear all
NCT02952508 2026-03-18

CLOVER-WaM

Cellectar Biosciences, Inc.

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡